Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSAS Study: Low-dose chlormadinone acetate in active surveillance for low-risk prostate cancer
jRCTs061180024Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in prostate cancer (PCa) comparing Chlormadinone acetate 50 mg/day with Placebo (2 arms). Primary endpoint: Rate of continued active surveillance. Started Mar 2014; status: completed.
02
Drugs
chlormadinone acetate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs061180024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180024.